<DOC>
	<DOCNO>NCT02942849</DOCNO>
	<brief_summary>Prospective , non-comparative , multi-centre , multi-country , observational post-authorization study , correlate predictive factor number oocytes relation gonadotropin dose administer use new r-hFSH product ( Bemfola® ) ovarian stimulation GnRH-antagonists pituitary suppression</brief_summary>
	<brief_title>Post-Authorisation Study Use Bemfola® Human Assisted Reproductive Technology</brief_title>
	<detailed_description>This prospective , non-comparative , multi-centre , multi-country , observational post-authorization study Germany Austria . The study evaluate use follitropin alfa ( Bemfola® ) control ovarian stimulation IVF/ICSI . About 30 ART centre involve study . Upon site initiation , investigator site enrol subject meet inclusion criterion . As observational study , additional treatment diagnostic procedure perform subject investigator ' local routine clinical practice . The decision start ART treatment use Bemfola® control ovarian hyperstimulation ( COH ) follow GnRH antagonist protocol make independently investigator per ART centre 's protocol , precede patient enrollment study .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<criteria>Female subject justify IVF/ICSI treatment Age 18 year ( inclusive ) time screen visit Signed informed patient consent Received Bemfola® ovarian stimulation Pituitary suppression GnRHantagonists Hypersensitivity active substance follitropin alfa , FSH excipients Tumours hypothalamus pituitary gland Ovarian enlargement ovarian cyst due polycystic ovarian syndrome Gynaecological haemorrhages unknown aetiology Ovarian , uterine mammary carcinoma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Bemfola</keyword>
	<keyword>r-hFSH</keyword>
	<keyword>Oocytes</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>OHSS</keyword>
</DOC>